title: [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
abstract: OBJECTIVE
  To investigate the therapeutic effect and safety of Sorafenib in the treatment of tumor recurrence after orthotopic liver transplantation (OLT).
  
  
  METHODS
  Between January, 2009 and June, 2011, 10 patients with tumor recurrence after OLT were treated with Sorafenib (group A) and another 8 recipients received no Sorafenib treatment (group B); 25 patients with hepatocellular carcinoma (HCC) also received Sorafenib treatment (group C). The tumor-bearing survival time, adverse effect and toxicity associated with sorafenib were compared between the 3 groups.
  
  
  RESULTS
  In group A, the median tumor-bearing survival time was 10 months (5-22 months), as compared to 4 months (1-8 months) in group B and 4 months (2-21 months) in group C, showing a significant difference in the survival time among the 3 groups (Kaplan-Meier, log-rank test, P=0.045). No recipient experienced acute graft rejection, but one recipient in group A died due to gastrointestinal bleeding. No significant difference was found in adverse effects associated with Sorafenib between groups A and C (P<0.05).
  
  
  CONCLUSIONS
  Sorafenib can prolong the survival time of patients with tumor recurrence after OLT without increasing the risk of acute graft rejection.
authors.affiliation: Department of Hepatobiliary Surgery, Southern Medical University, Guangzhou, China. lixhly@hotmail.com
authors.forename: Xiang-hong
authors.initials: XH
authors.lastname: Li
authors.forename: Ke-bo
authors.initials: KB
authors.lastname: Zhong
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Ding-hua
authors.initials: DH
authors.lastname: Yang
authors.forename: Jie
authors.initials: J
authors.lastname: Zhou
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011184:Postoperative Period; D000077157:Sorafenib; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib